Skip to main content
ImmuneCited

N-Acetylcysteine für Acute Bronchitis

B Evidenz Mindestens eine randomisierte Studie unterstützt dies, mit überwiegend konsistenten Ergebnissen.

Meta-analyses associate NAC supplementation with lower inflammatory markers and improved oxygenation in respiratory patients. Its well-established mucolytic properties support airway clearance in acute bronchitis. NAC is an FDA-approved mucolytic agent with a long safety record.

<\/script>\n
`; }, get iframeSnippet() { const domain = 'immunecited.com'; const params = 'ingredient\u003Dnac\u0026condition\u003Dacute\u002Dbronchitis'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

B

Fazit

Meta-analyses associate NAC supplementation with lower inflammatory markers and improved oxygenation in respiratory patients. Its well-established mucolytic properties support airway clearance in acute bronchitis. NAC is an FDA-approved mucolytic agent with a long safety record.

Key Study Findings

Review
N-acetylcysteine in paediatrics: a review of efficacy, safety and dosing strategies in respiratory care.
Dose: 20 mg/kg/day acute; 200 mg TID chronic vs.: None Outcome: Efficacy in pediatric respiratory diseases Wirkung: None None

Population: Children with acute/chronic respiratory diseases

Other n=270 8 weeks
N-acetyl-L-cysteine and lauric acid; effective antioxidant and antimicrobial feed additives for juvenile Pacific white shrimp …
Dose: 0.2% supplementation vs.: Control diet at LSD and HSD Outcome: Growth, immune and antioxidant response in shrimp Wirkung: None None

Population: Pacific white shrimp (L. vannamei) at high stocking density

In Vitro
Improving in vitro induction efficiency of human primordial germ cell-like cells using N2B27 or NAC-based …
Dose: None vs.: GK15 induction without NAC Outcome: hPGCLC induction efficiency Wirkung: None None

Population: Human iPSCs (in vitro)

Review
Cautious Hope for Cannabidiol (CBD) in Rheumatology Care.
Dose: Cannabidiol (CBD) vs.: None Outcome: Pain and inflammation in rheumatic diseases Wirkung: None None

Population: Patients with rheumatic diseases

Randomized Controlled Trial n=333 1.0 weeks Double-blind
Intravenous N-acetylcysteine in respiratory disease with abnormal mucus secretion.
Dose: 600 mg vs.: placebo and ambroxol Outcome: Sputum viscosity and expectoration difficulty Wirkung: None p<0.001

Population: Patients with respiratory disease and abnormal mucus

animal study (controlled experiment) n=120 3 weeks
Effects of N-acetyl-l-cysteine on chronic heat stress-induced oxidative stress and inflammation in the ovaries of …
Dose: 1 g/kg NAC in basal diet vs.: Placebo Wirkung: None None

Key Statistics

10

Studien

1500

Teilnehmer

Positive

B

Bewertung

Referenced Papers

Arthritis care & … 2023 36 Zitierungen
Phytomedicine : international … 2008 100 Zitierungen
Cardiovascular research 2006 42 Zitierungen

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

Übliche Dosierungen

general:
600-1,200 mg/day
respiratorysupport:
600 mg 2-3x/day

Obergrenze: No established UL; doses up to 1,800 mg/day widely studied

In der Forschung untersuchte Dosierungen

Dosierung Dauer Wirkung N
20 mg/kg/day acute; 200 mg TID chronic -- Positive --
0.2% supplementation 8 weeks Positive 270
None -- Positive --
Cannabidiol (CBD) -- Mixed --
600 mg 1.0 weeks Mixed 333
1 g/kg NAC in basal diet 3 weeks Positive 120
None -- Mixed --
1000 mg/kg in basal diet 3 weeks Positive 120

Beste Einnahmezeit: Between meals on empty stomach for optimal absorption

Safety & Side Effects

Gemeldete Nebenwirkungen

  • Gastrointestinal discomfort (nausea, diarrhea)
  • Unpleasant sulfur taste/smell
  • Headache
  • Rare: bronchospasm (in asthma patients, inhaled form)

Bekannte Wechselwirkungen

  • Nitroglycerin (may enhance vasodilatory and headache effects)
  • Activated charcoal (reduces NAC absorption)
  • Anticoagulants (theoretical effect on platelet function)

Tolerierbare Höchstaufnahmemenge: No established UL; doses up to 1,800 mg/day widely studied

Konsultieren Sie immer Ihren Arzt, bevor Sie ein Nahrungsergänzungsmittel einnehmen.Konsultieren Sie immer Ihren Arzt, bevor Sie ein Nahrungsergänzungsmittel einnehmen.

Frequently Asked Questions

Does N-Acetylcysteine help with Acute Bronchitis?
Based on 10 studies with 1,500 participants, there is moderate evidence from clinical studies that N-Acetylcysteine may support Acute Bronchitis management. Our evidence grade is B (Good Evidence).
How much N-Acetylcysteine should I take for Acute Bronchitis?
Studies have used various dosages. A commonly studied range is 600-1,200 mg/day. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of N-Acetylcysteine?
Reported side effects may include Gastrointestinal discomfort (nausea, diarrhea), Unpleasant sulfur taste/smell, Headache, Rare: bronchospasm (in asthma patients, inhaled form). Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for N-Acetylcysteine and Acute Bronchitis?
We rate the evidence as Grade B (Good Evidence). This rating is based on 10 peer-reviewed studies with 1,500 total participants. The overall direction of effect is positive.

Andere Inhaltsstoffe für Acute Bronchitis

N-Acetylcysteine für andere Beschwerden

References

  1. [1] Shafaq Fatima. PLoS One. 2025. N-acetyl-L-cysteine and lauric acid; effective antioxidant and antimicrobial feed additives for juvenile Pacific white shrimp (Litopenaeus vannamei) cultured at high … doi:10.1371/journal.pone.0315819 PubMed
  2. [2] Francesca Benedetti et al.. Drugs Context. 2025. N-acetylcysteine in paediatrics: a review of efficacy, safety and dosing strategies in respiratory care. doi:10.7573/dic.2025-7-7 PubMed
  3. [3] Gege Yuan et al.. J Biomed Res. 2025. Improving in vitro induction efficiency of human primordial germ cell-like cells using N2B27 or NAC-based medium. doi:10.7555/JBR.38.20240433 PubMed
  4. [4] Mary-Ann Fitzcharles et al.. Arthritis Care Res (Hoboken). 2023. Cautious Hope for Cannabidiol (CBD) in Rheumatology Care. doi:10.1002/acr.24176 PubMed
  5. [5] Xianhong Cao et al.. Poult Sci. 2023. Effects of N-acetyl-l-cysteine on chronic heat stress-induced oxidative stress and inflammation in the ovaries of growing pullets. doi:10.1016/j.psj.2022.102274 PubMed
  6. [6] W Tang et al.. Eur Rev Med Pharmacol Sci. 2023. Intravenous N-acetylcysteine in respiratory disease with abnormal mucus secretion. doi:10.26355/eurrev_202306_32628 PubMed
  7. [7] Matthew F McLaughlin et al.. Alcohol Clin Exp Res. 2022. Correlates of high phosphatidylethanol (PEth) levels and their concordance with self-reported heavy alcohol consumption among men who have sex with … doi:10.1111/acer.14891 PubMed
  8. [8] Yulan Zhao et al.. J Therm Biol. 2021. Effects of N-acetyl-l-cysteine on heat stress-induced oxidative stress and inflammation in the hypothalamus of hens. doi:10.1016/j.jtherbio.2021.102927 PubMed
  9. [9] Geetika Garg et al.. Can J Physiol Pharmacol. 2018. N-acetyl-l-cysteine attenuates oxidative damage and neurodegeneration in rat brain during aging. doi:10.1139/cjpp-2018-0209 PubMed
  10. [10] Jie Ma et al.. Nat Prod Commun. 2011. Simultaneous quantification of Echinacea species, Flos Lonicerae, Radix Scutellaria and Fructus Forsythiae combinations by rapid resolution liquid chromatography. PubMed
  11. [11] Taofikat B Agbabiaka et al.. Phytomedicine. 2008. Pelargonium sidoides for acute bronchitis: a systematic review and meta-analysis. doi:10.1016/j.phymed.2007.11.023 PubMed
  12. [12] Yao Sun et al.. Cardiovasc Res. 2006. Oxidative stress in aldosteronism. doi:10.1016/j.cardiores.2006.03.007 PubMed
  13. [13] Raja Jaber. Prim Care. 2002. Respiratory and allergic diseases: from upper respiratory tract infections to asthma. doi:10.1016/s0095-4543(01)00008-2 PubMed
  14. [14] Maciej Kupczyk et al.. Pol Merkur Lekarski. 2002. [Mucolytics in acute and chronic respiratory tract disorders. II. Uses for treatment and antioxidant properties]. PubMed
  15. [15] P Soepandi et al.. Respirology. 1998. The pattern of micro-organisms and the efficacy of new macrolide in acute lower respiratory tract infections. doi:10.1111/j.1440-1843.1998.tb00108.x PubMed
  16. [16] K P Völkl et al.. Fortschr Med. 1992. [Therapy of respiratory tract diseases with N-acetylcysteine. An open therapeutic observation study of 2,512 patients]. PubMed
  17. [17] H H Gerards et al.. Fortschr Med. 1991. [Therapy of bronchitis. Successful single-dosage treatment with N-acetylcysteine, results of an administration surveillance study in 3,076 patients]. PubMed

FDA-Haftungsausschluss: Diese Aussagen wurden nicht von der Food and Drug Administration bewertet. Die Produkte und Informationen auf dieser Website sind nicht dazu bestimmt, Krankheiten zu diagnostizieren, zu behandeln, zu heilen oder zu verhindern. Die dargestellten Evidenzbewertungen basieren auf unserer Analyse veröffentlichter begutachteter Forschung und stellen keine medizinische Beratung dar. Konsultieren Sie immer Ihren Arzt, bevor Sie mit der Einnahme von Nahrungsergänzungsmitteln beginnen.